Convalescent Plasma May Cut Deaths in Hematologic Cancer and COVID - 19
Lower 30 - day mortality seen in hospitalized adults, including those admitted to ICU, requiring mechanical ventilation (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 21, 2021 Category: Respiratory Medicine Tags: Infections, Oncology, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data
Guidelines for the treatment of BRCA-mutated breast cancer have been updated to incorporate the recent significant results from the OlympiA trial with olaparib (Lynparza).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate
Patients with non-small-cell lung cancer may respond more quickly to neoadjuvant durvalumab combined with stereotactic body radiotherapy than to immunotherapy alone, an early industry-funded trial suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 21, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Convalescent Plasma Saves Lives in Blood Cancer and COVID-19 Convalescent Plasma Saves Lives in Blood Cancer and COVID-19
Among patients with blood cancers who had COVID and were placed on ventilators, the use of convalescent plasma reduced the risk for death by 68%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Convalescent Plasma May Cut Deaths in Hematologic Cancer and COVID-19
MONDAY, June 21, 2021 -- For hospitalized patients with hematologic cancers and COVID-19, convalescent plasma therapy is associated with lower 30-day mortality, according to a study published online June 17 in JAMA Oncology. Michael A. Thompson,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2021 Category: Pharmaceuticals Source Type: news

Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

21-Gene Assay and Breast Cancer Mortality in DCIS 21-Gene Assay and Breast Cancer Mortality in DCIS
Could this genetic assay help identify which DCIS patients are most at risk for breast cancer mortality?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Success for a New Type of Checkpoint Inhibitor Success for a New Type of Checkpoint Inhibitor
Promising results in a study of>700 treatment-naive advanced melanoma patients.Medscape Blogs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2021 Category: Consumer Health News Tags: Hematology-Oncology Blog Source Type: news

Prolonged COVID-19 Common Among Patients With Lymphoma Prolonged COVID-19 Common Among Patients With Lymphoma
Approximately a third of patients with B-cell non-Hodgkin lymphoma require hospitalization for COVID-19 beyond 30 days. Older age and anti-CD20 therapy are key risk factors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Key Strategies for Managing Breast Cancer Brain Metastases Key Strategies for Managing Breast Cancer Brain Metastases
Breast cancer specialist Kevin M. Kalinsky, MD, discusses the interplay of tumor characteristics and treatment options.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

DCIS: Biosignature Helps Guide Post-Lumpectomy Decisions DCIS: Biosignature Helps Guide Post-Lumpectomy Decisions
A new biosignature tool helps with treatment decisions after lumpectomy for ductal carcinoma in situ (DCIS), eg, by identifying those who can skip radiotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Cost of More Surveillance Scanning: Patients' Mental Health The Cost of More Surveillance Scanning: Patients' Mental Health
We think scans reassure patients. But in reality, every scan is also a chance for a patient to realize their cancer has come back.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Association of convalescent plasma therapy with survival in patients with blood cancers, COVID-19
(JAMA Network) What The Study Did: Researchers evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic (blood) cancers and COVID-19. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2021 Category: Cancer & Oncology Source Type: news

' Bright Spots' Across US Have Cut Cancer Racial Inequities: How?'Bright Spots' Across US Have Cut Cancer Racial Inequities: How?
Racial inequities in cancer mortality are not inevitable, even in the race-divided United States. Some areas have successfully equalized the odds for Black patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Radical Prostatectomy Shifting to Higher-Risk Cases in Era of Active Surveillance Radical Prostatectomy Shifting to Higher-Risk Cases in Era of Active Surveillance
There has been a trend towards increasing use of radical prostatectomy in men with unfavorable-intermediate- and high-risk disease, according to a time-trends analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 16, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Screening Uptake, Not Biology, Behind Higher Risk of Colon Cancer in Black People Screening Uptake, Not Biology, Behind Higher Risk of Colon Cancer in Black People
The reported higher risk of colorectal cancer in African Americans compared to Whites is likely not related to biology but rather to uptake of screening, a US study suggests.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

' Bright Spots' Have Equalized Race Cancer Death Rates:  How?'Bright Spots' Have Equalized Race Cancer Death Rates:  How?
Racial inequities in cancer mortality are not inevitable, even in the race-divided United States. Some areas have successfully equalized the odds for Black patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Remarkable' Results for Targeted Therapy of Rare CNS Tumors'Remarkable' Results for Targeted Therapy of Rare CNS Tumors
The results come from three small studies of targeted therapy for papillary craniopharyngiomas (PCPs), gliomas and neuroblastomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Protecting Your Cancer Patients From the Plague Protecting Your Cancer Patients From the Plague
Should your cancer patients get the COVID vaccine? Short answer: yes.Medscape Blogs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology Blog Source Type: news

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline... Biopharmaceuticals, Oncology, Venture Capital KAHR Medical, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news

Saliva Test to Detect HPV-Associated Throat Cancer Saliva Test to Detect HPV-Associated Throat Cancer
A new clinically validated saliva test has demonstrated high accuracy in detecting HPV-positive oropharyngeal squamous cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Good Response to COVID-19 Vaccine After HSCT and CAR T-cell Tx Good Response to COVID-19 Vaccine After HSCT and CAR T-cell Tx
A small study shows relatively good responses among patients with blood cancers who underwent allogeneic hematopoeitic stem cells transplant (HSCT) and CAR T-cell therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Germline Genetic Testing for All Patients With Cancer? Germline Genetic Testing for All Patients With Cancer?
Genetic testing provides information that can inform cancer care, but the oncology community has been slow to adopt routine testing.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

CNN's Amanpour Being Treated for Ovarian Cancer CNN's Amanpour Being Treated for Ovarian Cancer
Christiane Amanpour, the chief international anchor for CNN, announced Monday at the start of her daily TV program that she's been diagnosed with ovarian cancer.WebMD Health News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Check Your Assumptions at the Door,' Advises Outlier Patient'Check Your Assumptions at the Door,' Advises Outlier Patient
A young Black woman diagnosed with melanoma twice before she turned 30 describes how off-the-mark comments from healthcare providers and others led her to feel marginalized and silenced.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Impressive Results' With CAR T-cell in R/R Follicular Lymphoma'Impressive Results' With CAR T-cell in R/R Follicular Lymphoma
Updated results show that patients who received the novel CAR T-cell therapy had significantly improved overall survival than comparable patients who received other current therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant and Adjuvant Treatment Approaches for HCC Neoadjuvant and Adjuvant Treatment Approaches for HCC
Learn more about the current neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma and the promising new options on the horizon.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Topical HDAC Inhibitor Reduced BCC Size in Early Study Topical HDAC Inhibitor Reduced BCC Size in Early Study
Surgical excision is the preferred treatment for BCC, but there is still a need for noninvasive treatment options, the investigator pointed out.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Oncologists Underestimate Patients' Use of Complementary Tx Oncologists Underestimate Patients' Use of Complementary Tx
Oncologists underestimate patients'use of complementary and alternative medicine and often have different opinions about potential benefits.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia
Patients with beta thalassemia who are not dependent on transfusions also derive benefit from the drug, showing improved hemoglobin levels and a reduced need for blood transfusions.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Zanubrutinib Better Than Ibrutinib in CLL/SLL? Zanubrutinib Better Than Ibrutinib in CLL/SLL?
An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Dr Kathy Miller shares the'biggest news in the breast cancer world'from ASCO, with presented data showing the benefit of olaparib in patients with high-risk,BRCA-mutated HER2-negative disease.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

LDCT Lung Cancer Screening May ID Aortic Stenosis Risk LDCT Lung Cancer Screening May ID Aortic Stenosis Risk
Using low-dose computed tomography (LDCT) to screen for aortic valve calcification during a lung cancer screening could identify those at risk for aortic stenosis, new research suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 11, 2021 Category: Cancer & Oncology Tags: Internal Medicine News Source Type: news

AI Could Sharply Reduce Mammography Workload AI Could Sharply Reduce Mammography Workload
Using AI to help analyze mammograms and tomosynthesis could eliminate up to 70% of radiology workload in breast cancer screening.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 11, 2021 Category: Cancer & Oncology Tags: Radiology News Source Type: news

FDA approves isatuximab-irfc for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves new dosing regimen for pembrolizumab
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
Oncology / Hematology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves brigatinib for ALK-positive metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news